Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: OTC US
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Neurologix Inc

+ Add to Watchlist

NRGXQ:US

0.0040 USD 0.00000.00%

As of 20:10:00 ET on 02/24/2015.

Snapshot for Neurologix Inc (NRGXQ)

Open: 0.0040 Day's Range: 0.0040 - 0.0040 Volume: 28,012
Previous Close: 0.0040 52wk Range: 0.0001 - 0.0100 1-Yr Rtn: +166.67%

Stock Chart for NRGXQ

No chart data available.
  • NRGXQ:US 0.0040
  • 1D
  • 1M
  • 1Y
0.0040
Interactive NRGXQ Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for NRGXQ

Current P/E Ratio (ttm) -
Estimated P/E(12/2011) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.4400
Est. EPS (USD) (12/2011) -
Est. PEG Ratio -
Market Cap (M USD) 0.11
Shares Outstanding (M) 28.00
30 Day Average Volume 23,637
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement -
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for NRGXQ

No data available

Company Profile & Key Executives for NRGXQ

Neurologix, Inc. is developing treatments for disorders of the brain and central nervous system using gene therapy and other alternative therapies. The Company's initial development efforts are focused on gene therapy for treating Parkinson's disease and epilepsy. Neurologix's core technology, NLX, is currently being tested in a human clinical trial to treat Parkinson's disease.

Clark A JohnsonChairman/CEOChristine V SapanExec VP/Chief Development Ofcr
More Company Profile & Key Executives for NRGXQ

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil